image credit: Vecteezy

PHE study finds COVID-19 vaccines ‘highly effective’ in at-risk groups

July 12, 2021


The study included one million people in at-risk groups, with those included in the study having underlying health conditions and more severe forms of illness.

Conditions such as diabetes, severe asthma, chronic heart disease, chronic kidney disease, chronic liver disease, neurological disease and diseases or therapies that weaken the immune system have been associated with an increased risk of hospitalisation or death with COVID-19.

Overall, the study found vaccine effectiveness against symptomatic disease in at-risk groups is approximately 60% after one dose of either the AstraZeneca or Pfizer/BioNTech vaccine.

Read More on Pharma Times